Monday, April 19, 2010

Sequenom Center for Molecular Medicine - potential to replace amniocentesis with safe non-invasive tests

Sequenom, Inc, a genetic analysis company started in 1996 holds the key to delivering highly-accurate non-invasive prenatal diagnostics that can eliminate the need for amnio, CVS and cordocentesis that can result in spontaneous abortion or pregnancy complications.

Sequenom already launched the cystic fibrosis, Rhesus-D and sex determination tests at its Center for Molecular Medicine in Michigan. It is expected that the Down's Syndrome test will hit the market this year. And then it may be possible to diagnose 1,400+ diseases at the prenatal level.
Women worldwide will salute such a development, because it will give them piece of mind and confidence during pregnancy with no side effects.